Global Epinephrine Auto-Injector Market - Focused Insights 2024-2029

131 pages

4 tables

32 charts

5 region

18 countries

14 company

04 segments

Purchase Options

$2990.00
$3500.00
$4500.00
$2000.00

Have a question?

Please get in touch with our team in case of any queries

+1-312-235-2040

THE GLOBAL EPINEPHRINE AUTO-INJECTOR MARKET WAS VALUED AT USD 2.05 BILLION IN 2023 AND IS EXPECTED TO REACH USD 3.40 BILLION BY 2029, GROWING AT A CAGR OF 8.82% DURING THE FORECAST PERIOD.

The Epinephrine Auto-Injector Market Size, Share & Trend Analysis Report By

  • Dosage: High Dose and Low Dose
  • Age Group: Below 6 years, Between 6 – 12 years, and Above 12 years
  • End-user: Individuals, Hospitals & Clinics, and Others
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

Customize this Report

This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize

EPINEPHRINE AUTO-INJECTOR MARKET REPORT SCOPE

REPORT ATTRIBUTEDETAILS
Market Size (2029)USD 3.40 Billion
Market Size (2023)USD 2.05 Billion
CAGR (2023-2029)8.82%
HISTORIC YEAR2020-2022
BASE YEAR2023
FORECAST YEAR2024-2029
MARKET SEGMENTS BYDosage, Age-Group, End-User, and Geography
GEOGRAPHIC ANALYSISNorth America, Europe, APAC, Latin America, and Middle East & Africa
KEY PLAYERSViatris (Mylan), Teva Pharmaceuticals, Amneal Pharmaceuticals, Bausch & Lomb, ALK Abello
Interested in this Report?

Download a Sample!

MARKET INSIGHTS

The global epinephrine auto-injector market was valued at USD 2.05 billion in 2023 and is expected to reach USD 3.40 billion by 2029, growing at a CAGR of 8.82% during the forecast period. The market growth is mainly attributable to the rising prevalence of anaphylaxis across demographics. Globally, allergies caused by food items, food additives, latex, and dust are increasing at a steady rate. Such allergies, including anaphylaxis, are most common in industrially developed countries such as the U.S. and the U.K. The rising number of such allergy cases and the popularity of epinephrine auto-injectors as the first-line treatment of anaphylaxis is expected to contribute to the increasing market share of the global epinephrine auto-injectors market during the forecast period.

Epinephrine auto-injector is a device used to manage potentially life-threatening anaphylactic reactions such as anaphylaxis. The device contains a measured dose of epinephrine (adrenaline), medication as the first-line therapy for anaphylaxis. The rising incidence/prevalence of anaphylaxis globally is influencing the higher uptake of epinephrine auto-injectors for emergency management of anaphylaxis across multiple age groups.

MARKET TRENDS & DRIVERS

Increasing Demand for Epinephrine Auto-injectors at Pharma/Retail stores

The increasing demand for generic epinephrine auto-injectors at pharmaceutical and retail stores reflects a growing awareness of the importance of accessibility and affordability in emergency medical care. As more individuals recognize the need for epinephrine to manage allergic emergencies such as anaphylaxis, there is a heightened demand for cost-effective alternatives to brand-name auto-injectors. Generic epinephrine auto-injectors offer a more affordable option for patients, particularly those without adequate insurance coverage or facing high out-of-pocket costs. As a result, pharmaceutical and retail stores are witnessing a surge in consumer demand for these generic alternatives. Patients actively seek out these products to access life-saving medication without financial burden. Moreover, the increased availability of generic epinephrine auto-injectors at pharmaceutical and retail stores is driven by efforts to expand access to essential medications. Additionally, the convenience and accessibility of purchasing generic epinephrine auto-injectors at retail stores further increase demand. Overall, the increasing demand for generic epinephrine auto-injectors at pharmaceutical and retail stores underscores the importance of affordability and accessibility in emergency medical care. By providing cost-effective alternatives to brand-name auto-injectors, generic products help ensure that all individuals at risk of anaphylaxis have access to the life-saving medication they need to manage allergic emergencies effectively.

Customization and Personalization of Epinephrine Auto-injectors

Customization and personalization of epinephrine auto-injectors represent a significant opportunity for enhancing patient experience and improving treatment outcomes. One customization aspect involves dosage adjustments, where auto-injectors can offer adjustable dosage options to cater to individuals with varying sensitivity to allergens or specific medical needs. This flexibility ensures that patients receive the appropriate dose of epinephrine tailored to their unique requirements, optimizing treatment efficacy. Additionally, customizing the form factor and design of auto-injectors can improve usability and acceptance among different patient groups. For instance, pediatric patients or individuals with mobility limitations may benefit from compact and ergonomic designs that are easier to handle and administer. By considering patients' diverse needs and preferences, manufacturers can design more intuitive and user-friendly auto-injectors, ultimately reducing barriers to self-administration. Tailoring needle length and gauge options in auto-injectors is another aspect of customization that can enhance patient comfort and safety. Offering a range of needle configurations allows patients to select the option that best suits their anatomy and comfort levels, minimizing discomfort and the risk of needlestick injuries. This personalized approach to needle design ensures that patients can administer epinephrine with confidence and minimal discomfort during emergencies. By tailoring auto-injector features and functionalities to individual needs and preferences, manufacturers can better meet the diverse requirements of patients and caregivers, ultimately improving the accessibility and usability of these life-saving devices.

The Rise of Generic Epinephrine Auto-injectors

The availability of generic versions of epinephrine auto-injectors has been a positive development in improving access to life-saving medication for individuals at risk of severe allergic reactions. Generic versions typically offer more affordable alternatives to brand-name auto-injectors, making them more accessible to a broader range of patients. The introduction of generic epinephrine auto-injectors has helped address concerns about the high cost of brand-name devices, which could sometimes pose a barrier to access for some patients, particularly those without adequate insurance coverage. By providing lower-cost options, generic versions have made it easier for individuals to obtain the medication they need to manage severe allergies and potentially life-threatening situations. Furthermore, the availability of generic alternatives has stimulated competition in the market, prompting manufacturers to innovate and improve their products while also driving down prices. This competition has benefited patients, increasing affordability and expanding options for epinephrine auto-injectors. Overall, the availability of generic epinephrine auto-injectors is a significant advancement in improving access to essential medication for individuals with severe allergies. It underscores the importance of affordability and accessibility in ensuring all patients have access to the life-saving treatments they need.

INDUSTRY RESTRAINTS

High Cost of Auto-injectors & Multiple Alternatives for Injections

The high cost of auto-injectors and the availability of multiple alternatives for injections pose significant challenges for individuals managing various medical conditions, including anaphylaxis, autoimmune diseases, and certain chronic conditions requiring injectable medications. Epinephrine auto-injectors, which are commonly used to treat anaphylaxis, have been subject to increased scrutiny due to their high cost. Brand-name auto-injectors can be prohibitively expensive for many patients, leading to concerns about affordability and access to life-saving medication. Despite efforts to introduce generic versions to the market, the cost of epinephrine auto-injectors remains a barrier for some individuals, particularly those without adequate insurance coverage. The high cost of auto-injectors and the availability of multiple alternatives for injections highlight the importance of considering factors such as affordability, accessibility, and individual patient preferences when selecting a treatment option. In conclusion, while auto-injectors offer convenience and ease of use for individuals requiring injectable medications, the high cost of these devices underscores the need for greater affordability and accessibility in healthcare. By addressing cost barriers and exploring alternative injection methods, healthcare providers and policymakers can help ensure that all patients have access to the medications they need to manage their conditions effectively.

SEGMENTATION INSIGHTS

INSIGHT BY DOSAGE TYPE

The global epinephrine auto-injector market by dosage type is segmented into high dose and low dose. The high-dose segment holds the largest share in 2023. The rising incidence/prevalence of anaphylaxis in adults, mainly in the elderly, is the primary factor driving the growth of the high-dose segment of the global epinephrine auto-injector market. Guidelines in several countries for the management of anaphylaxis generally recommend adrenaline as an immediate first-line treatment. As a result, healthcare professionals (HCPs) recommend a higher and safer dose (usually 0.3 mg) of epinephrine auto-injectors when no other adrenaline for intramuscular administration is available.

INSIGHT BY AGE-GROUP TYPE

The global epinephrine auto-injector market by age group is categorized as below 6 years, between 6 – 12 years, and above 12 years. The above 12-year segment shows prominent growth, with the fastest-growing CAGR during the forecast period. This segment is growing due to a rise in the incidence of anaphylaxis emergencies in populations aged above 12 years. Several studies reported anaphylaxis in elderly people tends to be more frequently life-threatening and requires intensified medical intervention. Therefore, to manage the higher risk for fatal outcomes of anaphylaxis in the adult patient group, significantly in elderly people, it is expected that the growth of epinephrine auto-injectors will be driven at a steady rate.

INSIGHT BY END-USER TYPE

By end-user, the individual segment dominates and has the largest share of the global epinephrine auto-injector market. The segment is likely to grow due to the rising demand for self-management of anaphylaxis with epinephrine auto-injectors. Mostly, individuals carry epinephrine auto-injectors for the treatment of sudden anaphylaxis shock. As the anaphylaxis prevalence is rising rapidly worldwide across all patient groups, self-management is becoming increasingly important for managing anaphylaxis during emergencies at any point in time, irrespective of location. As a result, the individual end-user segment has become a major revenue generator for the global epinephrine auto-injector market. It is likely to grow at the same pace during the forecast period.

GEOGRAPHICAL ANALYSIS

North America accounted for over 79% of the share and stands first in the global epinephrine auto-injector market. The market in the region is dominated by branded and generic epinephrine auto-injectors for treating anaphylactic reactions. The availability of generic epinephrine auto-injectors is abundantly high in this region. The increasing prevalence of anaphylaxis and high healthcare spending enable high uptake of epinephrine auto-injectors as self-medication or through the recommendation of healthcare professionals.

COMPETITIVE LANDSCAPE

The global epinephrine auto-injector market report contains exclusive data on 14 vendors. The global epinephrine auto-injector market is highly consolidated and is characterized by a few established vendors holding most of the market share. Vendors are offering several branded and generic epinephrine auto-injectors. They compete based on regulatory approvals, safety features, accurate dosing, convenient use, technology up-gradation, marketing strategies, and distribution channels. Viatris (Mylan), Teva Pharmaceuticals, Amneal Pharmaceuticals, Bausch & Lomb, and ALK Abello are the key vendors in the market. These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on innovation and research activities.

Frequently Asked Questions

How big is the global epinephrine auto-injectors market?

The global epinephrine auto-injectors market was valued at USD 2.05 billion in 2023 and is expected to reach USD 3.40 billion by 2029.

What is the growth rate of the global epinephrine auto-injectors market?

The global epinephrine auto-injectors market is expected to grow at a CAGR of 8.82% during the forecast period.

Which region dominates the global epinephrine auto-injectors market?

North America dominates the global epinephrine auto-injectors market.

What are the key drivers of the global epinephrine auto-injectors market?

The rise of generic epinephrine auto-injectors, rising awareness of anaphylaxis & availability of innovative products, increasing awareness about self-injection with first-line of treatment, and rise in incidences of anaphylaxis and food allergies are the key drivers of the global epinephrine auto-injectors market.

Who are the major players in the global epinephrine auto-injectors market?

Viatris (Mylan), Teva Pharmaceuticals, Amneal Pharmaceuticals, Bausch & Lomb, and ALK Abello are the major players in the global epinephrine auto-injectors market.

The global epinephrine auto-injector market size is expected to grow at a CAGR of approximately 8.82% from 2023 to 2029.

Base Year: 2023

Forecast Year: 2024-2029

The report considers the present scenario of the global epinephrine auto-injector market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

VENDOR LIST

Key Vendors

  • Viatris
    • Business Overview
    • Product Offerings
  • Teva Pharmaceuticals
  • Amneal Pharmaceuticals
  • ALK-Abello
  • Bausch & Lomb

Other Prominent Vendors

  • DMK Pharmaceuticals
    • Business Overview
    • Product Offerings
  • Bioprojet Pharma
  • Kaleo
  • Novartis
  • Sanofi
  • Pfizer
  • Halozyme Therapeutics
  • Crossject SA
  • Lincoln Medical

SEGMENTATION & FORECAST

  • By Dosage
    • High Dose
    • Low Dose
  • By Age Group
    • Below 6 years
    • Between 6 – 12 years
    • Above 12 years
  • By End-user
    • Individuals
    • Hospitals & Clinics
    • Others

By Geography

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The U.K.
    • France
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • South Africa
    • Saudi Arabia

Exhibit 1: Projected Revenues of Epinephrine Auto-injectors in Global (2020 – 2029; $ Mn)

Exhibit 2: Market Size & Forecast – High Dose (2020 – 2029; $ Mn)

Exhibit 3: Market Size & Forecast – Low Dose (2020 – 2029; $ Mn)

Exhibit 4: Market Size & Forecast – Above 12 years (2020 – 2029; $ Mn)

Exhibit 5: Market Size & Forecast – Between 6 – 12 years (2020 – 2029; $ Mn)

Exhibit 6: Market Size & Forecast – Below 6 years (2020 – 2029; $ Mn)

Exhibit 7: Market Size & Forecast – Individuals (2020 – 2029; $ Mn)

Exhibit 8: Market Size & Forecast – Hospitals & Clinics (2020 – 2029; $ Mn)

Exhibit 9: Market Size & Forecast – Others (2020 – 2029; $ Mn)

Exhibit 10: Projected Revenues of Epinephrine Auto-injectors in N. America (2020 – 2029; $ Mn)

Exhibit 11: Projected Revenues of Epinephrine Auto-injectors in the US (2020 – 2029; $ Mn)

Exhibit 12: Projected Revenues of Epinephrine Auto-injectors in Canada (2020 – 2029; $ Mn)

Exhibit 13: Projected Revenues of Epinephrine Auto-injectors in Europe (2020 – 2029; $ Mn)

Exhibit 14: Projected Revenues of Epinephrine Auto-injectors in Germany (2020 – 2029; $ Mn)

Exhibit 15: Projected Revenues of Epinephrine Auto-injectors in France (2020 – 2029; $ Mn)

Exhibit 16: Projected Revenues of Epinephrine Auto-injectors in UK (2020 – 2029; $ Mn)

Exhibit 17: Projected Revenues of Epinephrine Auto-injectors in Spain (2020 – 2029; $ Mn)

Exhibit 18: Projected Revenues of Epinephrine Auto-injectors in Netherlands (2020 – 2029; $ Mn)

Exhibit 19: Projected Revenues of Epinephrine Auto-injectors in APAC (2020 – 2029; $ Mn)

Exhibit 20: Projected Revenues of Epinephrine Auto-injectors in Japan (2020 – 2029; $ Mn)

Exhibit 21: Projected Revenues of Epinephrine Auto-injectors in Australia (2020 – 2029; $ Mn)

Exhibit 22: Projected Revenues of Epinephrine Auto-injectors in S. Korea (2020 – 2029; $ Mn)

Exhibit 23: Projected Revenues of Epinephrine Auto-injectors in China (2020 – 2029; $ Mn)

Exhibit 24: Projected Revenues of Epinephrine Auto-injectors in Taiwan (2020 – 2029; $ Mn)

Exhibit 25: Projected Revenues of Epinephrine Auto-injectors in MEA (2020 – 2029; $ Mn)

Exhibit 26: Projected Revenues of Epinephrine Auto-injectors in Israel (2020 – 2029; $ Mn)

Exhibit 27: Projected Revenues of Epinephrine Auto-injectors in S. Africa (2020 – 2029; $ Mn)

Exhibit 28: Projected Revenues of Epinephrine Auto-injectors in Turkey (2020 – 2029; $ Mn)

Exhibit 29: Projected Revenues of Epinephrine Auto-injectors in L. America (2020 – 2029; $ Mn)

Exhibit 30: Projected Revenues of Epinephrine Auto-injectors in Brazil (2020 – 2029; $ Mn)

Exhibit 31: Projected Revenues of Epinephrine Auto-injectors in Argentina (2020 – 2029; $ Mn)

Exhibit 32: Projected Revenues of Epinephrine Auto-injectors in Mexico (2020 – 2029; $ Mn)

 

Tables

Table 1: Key Market Trends in Epinephrine Auto-injectors Market

Table 2: Key Market Enablers in Epinephrine Auto-injectors Market

Table 3: Key Market Constraints in Epinephrine Auto-injectors Market

Table 4: Strategic Recommendations in Epinephrine Auto-injectors Market

CHAPTER 1: Epinephrine Auto-injectors Market Overview

  • Executive Summary
  • Key Findings

CHAPTER 2: Epinephrine Auto-injectors Market

  • GLOBAL: Projected Revenue of Epinephrine Auto-injectors Market (2020-2029; $Millions)

CHAPTER 3: Epinephrine Auto-injectors Market Segmentation Data

  • GLOBAL: Projected Revenue by Dosage (2020-2029; $Millions)
    • High Dose
    • Low Dose
  • GLOBAL: Projected Revenue by Age-group (2020-2029; $Millions)
    • Below 6 years
    • Between 6 – 12 years
    • Above 12 years
  • GLOBAL: Projected Revenue by End-user (2020-2029; $Millions)
    • Individuals
    • Hospitals & Clinics
    • Others

CHAPTER 4: Key Regions Overview

  • North America: Projected Revenue of Epinephrine Auto-injectors Market (2020-2029; $Millions)
    • Projected Revenue of Epinephrine Auto-injectors Market in US
    • Projected Revenue of Epinephrine Auto-injectors Market in Canada
  • Europe: Projected Revenue of Epinephrine Auto-injectors Market (2020-2029; $Millions)
    • Projected Revenue of Epinephrine Auto-injectors Market in Germany
    • Projected Revenue of Epinephrine Auto-injectors Market in France
    • Projected Revenue of Epinephrine Auto-injectors Market in UK
    • Projected Revenue of Epinephrine Auto-injectors Market in Spain
    • Projected Revenue of Epinephrine Auto-injectors Market in Netherlands
  • APAC: Projected Revenue of Epinephrine Auto-injectors Market (2020-2029; $Millions)
    • Projected Revenue of Epinephrine Auto-injectors Market in Japan
    • Projected Revenue of Epinephrine Auto-injectors Market in Australia
    • Projected Revenue of Epinephrine Auto-injectors Market in South Korea
    • Projected Revenue of Epinephrine Auto-injectors Market in China
    • Projected Revenue of Epinephrine Auto-injectors Market in Taiwan
  • Middle East & Africa: Projected Revenue of Epinephrine Auto-injectors Market (2020-2029; $Millions)
    • Projected Revenue of Epinephrine Auto-injectors Market in Israel
    • Projected Revenue of Epinephrine Auto-injectors Market in South Africa
    • Projected Revenue of Epinephrine Auto-injectors Market in Turkey
  • Latin America: Projected Revenue of Epinephrine Auto-injectors Market (2020-2029; $Millions)
    • Projected Revenue of Epinephrine Auto-injectors Market in Brazil
    • Projected Revenue of Epinephrine Auto-injectors Market in Mexico
    • Projected Revenue of Epinephrine Auto-injectors Market in Argentina 

CHAPTER 5: Epinephrine Auto-injectors Market Prospects & Opportunities

  • Epinephrine Auto-injectors Market Opportunities & Trends
  • Epinephrine Auto-injectors Market Drivers
  • Epinephrine Auto-injectors Market Constraints

CHAPTER 6:  Epinephrine Auto-injectors Industry Overview

  • Epinephrine Auto-injectors Market - Competitive Landscape
  • Epinephrine Auto-injectors Market – Key Vendor Profiles
  • Epinephrine Auto-injectors Market – Other Prominent Vendors
  • Epinephrine Auto-injectors Market - Key Strategic Recommendations 

CHAPTER 7: Appendix

  • Research Methodology
  • Abbreviations
  • About Arizton

Select a license type that suits your business needs

Single User Licence

$2990.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email

5 User Licence

$3500.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Corporate Licence

$4500.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Datasheet Licence

$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Frequently Asked Questions

How big is the global epinephrine auto-injectors market?

The global epinephrine auto-injectors market was valued at USD 2.05 billion in 2023 and is expected to reach USD 3.40 billion by 2029.

What is the growth rate of the global epinephrine auto-injectors market?

The global epinephrine auto-injectors market is expected to grow at a CAGR of 8.82% during the forecast period.

Which region dominates the global epinephrine auto-injectors market?

North America dominates the global epinephrine auto-injectors market.

What are the key drivers of the global epinephrine auto-injectors market?

The rise of generic epinephrine auto-injectors, rising awareness of anaphylaxis & availability of innovative products, increasing awareness about self-injection with first-line of treatment, and rise in incidences of anaphylaxis and food allergies are the key drivers of the global epinephrine auto-injectors market.

Who are the major players in the global epinephrine auto-injectors market?

Viatris (Mylan), Teva Pharmaceuticals, Amneal Pharmaceuticals, Bausch & Lomb, and ALK Abello are the major players in the global epinephrine auto-injectors market.